Highest-materiality recent filing
Fuse Medical voluntarily deregisters common stock, suspends SEC reporting
Filed Form 15 to voluntarily deregister common stock and suspend Exchange Act reporting effective Sept 27, 2023.
Fuse Medical Q2 2023 net income $307,588 vs loss of $322,936 a year ago
Revenue rose 7% to $5.0M from $4.7M in Q2 2022.
Fuse Medical holds 2023 Annual Meeting; all director nominees elected and auditor ratified
All four director nominees elected with >98% votes for: Bosita, Brooks, Yellin, Reeg.
Fuse Medical reports FY 2022 net income of $3.1M, swing from prior-year loss; revenue down 9%
Net revenue $18.6M (-9% YoY); gross profit margin improved to 62% from 58%.
Fuse Medical appoints M&K PLLC as new auditor, replaces Armanino LLP
Armanino engagement mutually ended effective Nov 1, 2022; no disagreements or reportable events.
Fuse Medical Q3 net loss shrinks 99% to $9.4k; revenue up 7% to $4.5M
Net revenues $4.5M (+7% YoY); gross profit $3M (67% margin vs 56% in prior year).
Fuse Medical reports shareholder votes: all directors elected, auditor ratified
Renato V. Bosita, Jr., MD re-elected with 62,766,475 votes for, 295,105 against.
Fuse Medical appoints Lawrence S. Yellin as CFO, Treasurer, and board member
Lawrence S. Yellin appointed CFO, Treasurer, and board member effective April 4, 2022.
Fuse Medical enters $5M secured revolving credit facility with CNH Finance, matures 2025
$5M revolving credit facility, maturity January 1, 2025; subject to borrowing base.
Fuse Medical CFO and Director McLaughlin resigns; interim CFO engaged
William E. McLaughlin resigned as CFO and Director on Nov 29, 2021, with no disagreements.
Fuse Medical obtains waiver of EBITDA default; loan limit cut to $2.55M, term extended to Feb 2022
Lender waived default for failing to meet $600K minimum EBITDA for trailing twelve months ended Sep 30, 2021.
Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.
Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.
Effective April 4, 2022, John S. Gross ceased providing the Company with interim CFO services pursuant to the Company’s engagement agreement with CFO Consulting Partners, LLC.
On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the “Company”) as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries.
Max materiality 0.75 · Median 0.55 · Most common event earnings